Cladribine (CLAD)

DRUG2 trials

Sponsors

Stanford University, M.D. Anderson Cancer Center

Conditions

IDH1-Mutated MalignanciesMutationsRefractory Acute Myeloid LeukemiaRelapsed Acute Myeloid LeukemiaTargeted Therapy

Phase 1

Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

RecruitingNCT06561152

Stanford UniversityRefractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia

Start: 2025-02-10End: 2028-10-31Target: 20Updated: 2025-03-17

Phase 2

Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations

RecruitingNCT07032727

M.D. Anderson Cancer CenterIDH1-Mutated Malignancies, Mutations, Targeted Therapy

Start: 2025-09-12End: 2029-06-01Target: 68Updated: 2025-12-15

Related Papers

Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory Acute Myeloid Leukemia

Blood2025-11-03

Tagraxofusp and low-intensity chemotherapy for the treatment of CD123-positive relapsed or refractory acute myeloid leukemia.

Journal of Clinical Oncology2025-05-28